Archit Organosys
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Archit Organosys approved a preferential issue of up to 3,72,48,344 equity shares at ₹65 each through a share swap to acquire 1,86,24,172 shares, or 92.2%, of Archit Life Science. The swap represented about ₹242 crore of consideration, based on a ₹130 valuation for each Archit Life Science share, and was subject to shareholder and regulatory approvals. The board also approved increasing authorised share capital from ₹25 crore to ₹60 crore, subject to shareholder approval. Archit Life Science ceased to be a subsidiary in 2023 and remained a related-party counterparty in Archit Organosys's inter-corporate lending.
Powered by Tijori
Archit Organosys approved a preferential issue of up to 3,72,48,344 equity shares at ₹65 each through a share swap to acquire 1,86,24,172 shares, or 92.2%, of Archit Life Science. The swap represented about ₹242 crore of consideration, based on a ₹130 valuation for each Archit Life Science share, and was subject to shareholder and regulatory approvals. The board also approved increasing authorised share capital from ₹25 crore to ₹60 crore, subject to shareholder approval. Archit Life Science ceased to be a subsidiary in 2023 and remained a related-party counterparty in Archit Organosys's inter-corporate lending.
Powered by Tijori
Archit Organosys approved a preferential issue of up to 3,72,48,344 equity shares at ₹65 each, in a non-cash swap for 1,86,24,172 shares, or 92.20%, of Archit Life Science. The target shares were valued at ₹130 each, and the allotment was proposed for promoter, promoter-group and non-promoter recipients. The board also approved raising authorised share capital from ₹25 crore to ₹60 crore, subject to shareholder approval. Archit Life Science had ceased to be a subsidiary in June 2023 but remained a related party and the main inter-corporate loan counterparty. Archit Organosys reported FY26 revenue of ₹140.95 crore and net profit of ₹8.03 crore.
Powered by Tijori
Archit Organosys approved a preferential issue of up to 3,72,48,344 equity shares at ₹65 each, in a non-cash swap for 1,86,24,172 shares, or 92.20%, of Archit Life Science. The target shares were valued at ₹130 each, and the allotment was proposed for promoter, promoter-group and non-promoter recipients. The board also approved raising authorised share capital from ₹25 crore to ₹60 crore, subject to shareholder approval. Archit Life Science had ceased to be a subsidiary in June 2023 but remained a related party and the main inter-corporate loan counterparty. Archit Organosys reported FY26 revenue of ₹140.95 crore and net profit of ₹8.03 crore.
Powered by Tijori
Archit Organosys scheduled a board meeting for 3 September 2026 to consider and evaluate a proposal to raise funds through equity shares, warrants and other equity-linked securities. The possible routes included a preferential issue, private placement or another permitted mechanism, subject to required approvals. Revenue for FY26 was ₹140.95 crore and profit after tax was ₹8.03 crore. Current loans stood at ₹29.27 crore and cash at ₹1.37 crore at the end of FY26.
Powered by Tijori
Archit Organosys scheduled a board meeting for 3 September 2026 to consider and evaluate a proposal to raise funds through equity shares, warrants and other equity-linked securities. The possible routes included a preferential issue, private placement or another permitted mechanism, subject to required approvals. Revenue for FY26 was ₹140.95 crore and profit after tax was ₹8.03 crore. Current loans stood at ₹29.27 crore and cash at ₹1.37 crore at the end of FY26.
Powered by Tijori
Archit Organosys scheduled a board meeting for 3 September 2026 to consider raising funds through equity shares, share warrants and other equity-linked securities. The possible issue could be conducted through a preferential issue on a private-placement basis or another permitted route, subject to required approvals. The company reported FY26 revenue of ₹140.95 crore and profit after tax of ₹8.03 crore. Cash stood at ₹1.37 crore against borrowings of about ₹24.66 crore at the end of FY26.
Powered by Tijori
Archit Organosys scheduled a board meeting for 3 September 2026 to consider raising funds through equity shares, share warrants and other equity-linked securities. The possible issue could be conducted through a preferential issue on a private-placement basis or another permitted route, subject to required approvals. The company reported FY26 revenue of ₹140.95 crore and profit after tax of ₹8.03 crore. Cash stood at ₹1.37 crore against borrowings of about ₹24.66 crore at the end of FY26.
Powered by Tijori
June 30 (Reuters) - Archit Organosys Ltd ARCI.BO:
ARCHIT ORGANOSYS LTD - APPOINTS ANILBHAI PATEL AS CFO EFFECTIVE 1ST JULY 2025
ARCHIT ORGANOSYS LTD - AJAY PUNAMCHAND PATEL RESIGNS AS CFO EFFECTIVE 30TH JUNE 2025
Source text: ID:nBSEbjgtRr
Further company coverage: ARCI.BO
(([email protected];;))
June 30 (Reuters) - Archit Organosys Ltd ARCI.BO:
ARCHIT ORGANOSYS LTD - APPOINTS ANILBHAI PATEL AS CFO EFFECTIVE 1ST JULY 2025
ARCHIT ORGANOSYS LTD - AJAY PUNAMCHAND PATEL RESIGNS AS CFO EFFECTIVE 30TH JUNE 2025
Source text: ID:nBSEbjgtRr
Further company coverage: ARCI.BO
(([email protected];;))
Feb 26 (Reuters) - Archit Organosys Ltd ARCI.BO:
ARCHIT ORGANOSYS LTD - AJAY P PATEL RESIGNS AS CFO
Source text: ID:nBSE96KhHf
Further company coverage: ARCI.BO
(([email protected];;))
Feb 26 (Reuters) - Archit Organosys Ltd ARCI.BO:
ARCHIT ORGANOSYS LTD - AJAY P PATEL RESIGNS AS CFO
Source text: ID:nBSE96KhHf
Further company coverage: ARCI.BO
(([email protected];;))
March 27 (Reuters) - Archit Organosys Ltd ARCI.BO:
APPROVED DISINVESTMENT OF ENTIRE 50.01% STAKE IN UNIT NOVEL AND NANO XTREME SOLUTIONS LLP
Source text for Eikon: ID:nBSE5rj9r1
Further company coverage: ARCI.BO
(([email protected];))
March 27 (Reuters) - Archit Organosys Ltd ARCI.BO:
APPROVED DISINVESTMENT OF ENTIRE 50.01% STAKE IN UNIT NOVEL AND NANO XTREME SOLUTIONS LLP
Source text for Eikon: ID:nBSE5rj9r1
Further company coverage: ARCI.BO
(([email protected];))
March 5 (Reuters) - Archit Organosys Ltd ARCI.BO:
ARCHIT ORGANOSYS LTD - HDFC BANK HAS AGREED ENTERING INTO ONE TIME SETTLEMENT FOR FULL AND FINAL AMICABLE SETTLEMENT
ARCHIT ORGANOSYS LTD - HDFC HAS AGREED FOR CONSOLIDATED AMOUNT OF 25 MILLION RUPEES
Source text for Eikon: ID:nBSE6Mxgg5
Further company coverage: ARCI.BO
(([email protected];))
March 5 (Reuters) - Archit Organosys Ltd ARCI.BO:
ARCHIT ORGANOSYS LTD - HDFC BANK HAS AGREED ENTERING INTO ONE TIME SETTLEMENT FOR FULL AND FINAL AMICABLE SETTLEMENT
ARCHIT ORGANOSYS LTD - HDFC HAS AGREED FOR CONSOLIDATED AMOUNT OF 25 MILLION RUPEES
Source text for Eikon: ID:nBSE6Mxgg5
Further company coverage: ARCI.BO
(([email protected];))
Jan 30 (Reuters) - Archit Organosys Ltd ARCI.BO:
SUBSCRIBED TO RIGHT ISSUE OF ARCHIT LIFE SCIENCE
COST OF ACQUISITION 29.5 MILLION RUPEES
Source text for Eikon: ID:nBSE6fMtV6
Further company coverage: ARCI.BO
(([email protected];))
Jan 30 (Reuters) - Archit Organosys Ltd ARCI.BO:
SUBSCRIBED TO RIGHT ISSUE OF ARCHIT LIFE SCIENCE
COST OF ACQUISITION 29.5 MILLION RUPEES
Source text for Eikon: ID:nBSE6fMtV6
Further company coverage: ARCI.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Archit Organosys do?
Shri Chlochem Ltd is a key player in chemical manufacturing and exports, offering products like Monochloro Acetic Acid (MCA), Sodium Monochloro Acetate (SMCA), Pigment, and Shade Card.
Who are the competitors of Archit Organosys?
Archit Organosys major competitors are AG Ventures, Polson, Kanchi Karpooram, Par Drugs & Chem., Resonance Specialtie, Alkali Metals, Multibase India. Market Cap of Archit Organosys is ₹139 Crs. While the median market cap of its peers are ₹171 Crs.
Is Archit Organosys financially stable compared to its competitors?
Archit Organosys seems to be less financially stable compared to its competitors. Altman Z score of Archit Organosys is 3.56 and is ranked 5 out of its 8 competitors.
Does Archit Organosys pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Archit Organosys latest dividend payout ratio is 20.31% and 3yr average dividend payout ratio is 14.65%
How has Archit Organosys allocated its funds?
Companies resources are allocated to majorly unproductive assets like Short Term Loans & Advances
How strong is Archit Organosys balance sheet?
Balance sheet of Archit Organosys is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Archit Organosys improving?
The profit is oscillating. The profit of Archit Organosys is ₹5.05 Crs for Mar 2025, ₹3.34 Crs for Mar 2024 and ₹11.43 Crs for Mar 2023
Is the debt of Archit Organosys increasing or decreasing?
Yes, The net debt of Archit Organosys is increasing. Latest net debt of Archit Organosys is ₹26.19 Crs as of Mar-25. This is greater than Mar-24 when it was ₹20.7 Crs.
Is Archit Organosys stock expensive?
Archit Organosys is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Archit Organosys is 18.7, while 3 year average PE is 18.65. Also latest EV/EBITDA of Archit Organosys is 10.26 while 3yr average is 10.42.
Has the share price of Archit Organosys grown faster than its competition?
Archit Organosys has given better returns compared to its competitors. Archit Organosys has grown at ~31.55% over the last 7yrs while peers have grown at a median rate of 5.15%
Is the promoter bullish about Archit Organosys?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Archit Organosys is 65.88% and last quarter promoter holding is 65.88%.
Are mutual funds buying/selling Archit Organosys?
There is Insufficient data to gauge this.